NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. - Wikidata - wikimedia - TriplyDB

NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma.

NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma.

http://www.wikidata.org/entity/Q44484456

about

HDACs and the senescent phenotype of WI-38 cells.Clinical use and applications of histone deacetylase inhibitors in multiple myeloma Panobinostat for the treatment of multiple myeloma: the evidence to date Novel agents for multiple myeloma to overcome resistance in phase III clinical trials Bioactive heterocycles containing endocyclic N-hydroxy groups Novel therapeutic strategies for multiple myeloma From bench to bedside: lessons learned in translating preclinical studies in cancer drug development A phase 1/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple myeloma.Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma Histone deacetylase 3 as a novel therapeutic target in multiple myeloma.New insights into the treatment of multiple myeloma with histone deacetylase inhibitors.Histone modification enzymes: novel targets for cancer drugs.The DAC system and associations with multiple myeloma.Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma.Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy.Antitumor action of a novel histone deacetylase inhibitor, YF479, in breast cancer.The potential of panobinostat as a treatment option in patients with relapsed and refractory multiple myeloma.HDAC11 plays an essential role in regulating OX40 ligand expression in Hodgkin lymphoma.New insights, recent advances, and current challenges in the biological treatment of multiple myeloma.The role of DNA synthesis imaging in cancer in the era of targeted therapeutics Augmenting antitumor immune responses with epigenetic modifying agents.Histone deacetylase inhibitors in clinical development.Chaetocin: a promising new antimyeloma agent with in vitro and in vivo activity mediated via imposition of oxidative stress.Rational combination treatment with histone deacetylase inhibitors and immunomodulatory drugs in multiple myeloma.The histone deacetylase inhibitors LAQ824 and LBH589 do not require death receptor signaling or a functional apoptosome to mediate tumor cell death or therapeutic efficacy.Targeted therapy in multiple myeloma.Targeting signalling pathways for the treatment of multiple myeloma.Inhibition of histone deacetylase for the treatment of biliary tract cancer: a new effective pharmacological approach.Differential effects of histone deacetylase inhibitors in tumor and normal cells-what is the toxicological relevance?Histone deacetylase inhibitors: insights into mechanisms of lethality.Strategies for the Optimization of Natural Leads to Anticancer Drugs or Drug Candidates.Lenalidomide in multiple myeloma.Investigational treatments for multiple myeloma.The evolving role of lenalidomide in the treatment of hematologic malignancies.The aggresome pathway as a target for therapy in hematologic malignancies.Preclinical studies of novel targeted therapies.From the bench to the bedside: emerging new treatments in multiple myeloma.Gene expression-based prediction of myeloma cell sensitivity to histone deacetylase inhibitors.Biologic sequelae of I{kappa}B kinase (IKK) inhibition in multiple myeloma: therapeutic implications.Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid Malignancies

P2860

Q24810847-2A27CD7B-9E6A-481C-9475-B1C7CA2A95C2 Q26745930-0DF2CA80-B0D7-4FD3-B00C-BACC84F35CA9 Q26778674-55C1C59B-E2A6-4FD1-A056-6AB0807ACB7A Q26822754-CF16A2B3-EB97-4823-8515-84FEE6E59884 Q27025241-0D71A2E8-10E8-4258-9DF1-502ECDE1E6DF Q28081590-EA53F271-F5C3-4ABB-97D2-CADB5AAF5CD5 Q28533949-B60F3560-728B-48C6-9003-F66692C60686 Q33410997-6F10242E-4BCA-4686-898C-97B043A39077 Q33854012-86983E71-B32C-4CAD-A42D-AF5D03140756 Q34194704-9221B06F-267C-4D03-8E1C-5734033DB217 Q34224278-1738692D-E987-4411-8700-5FD42B3A63F7 Q34322087-FEFA69E1-3BD8-4DEA-B31B-B9D8C7179E98 Q34414447-B9C835F6-926A-41C1-A271-21EFF5205CF6 Q34441748-A761325F-C5F2-4E30-A77E-BC7B1DEDED48 Q34488424-137ACBBD-DDBA-4028-B004-FEA9B9C1819F Q34528291-E8A6C5A7-ACC0-4BAE-8F82-440A3533287D Q34602263-BE7C4289-DA9D-476E-8A98-8D05852201DF Q34707183-1CCD2D68-335D-4D8D-A1F5-74BE30E68AC5 Q34773850-4CB5EE03-DCB8-4CCC-86C9-48AA8DDF55F9 Q34907192-4917876A-9D59-49C8-B84F-F2EA8500E4BE Q35048054-CECD54FD-B68E-43F3-B8A2-17EFA277F3F3 Q35609717-57DBAE09-1D73-47F9-9A51-A32E901EDC8F Q35750893-27CECFDE-92A3-4291-BAC0-02622B896DED Q35764582-21421589-AC0A-45F1-B9FA-960257566680 Q36087855-B56A2236-8EA3-48C9-867D-3A97581F0535 Q36108614-4A534882-5512-4197-94A7-12CF9C13CD9C Q36150866-F656E40A-5658-4185-8D98-31ADA2E079B0 Q36177918-5D420B16-D83C-4951-B56B-7CCC488DAD82 Q36179533-C0F8BB97-BCD0-4CA7-8BE1-B7B9D9632530 Q36219726-2FC4597A-84AD-4DC8-821B-8DC51574D550 Q36372894-7E95D354-6368-486A-ADF3-459F381F9000 Q36573818-B42D6BA8-37A8-40D0-AEE1-82F3FAF14089 Q36654336-BEDDB7BF-9AEF-4343-BEC3-7C651379A148 Q36739807-84923F7F-A0EF-4EB8-9060-FB78325ABA3A Q36984494-FB6D5E5D-2F03-4BCD-B17D-94E358E56BA2 Q36998210-758426D2-A05B-49E3-959D-5125CF8B2740 Q37028598-503174EF-E5A9-4314-B4AB-FCC04D799F3A Q37083880-94277295-6E1D-4AF2-9319-D203E587092F Q37201984-9A5B6183-31BD-4479-8AB6-59C380ECCFC0 Q37226511-8248A4DE-76AD-450A-AC47-2477555E2DB8

P2860

NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma.

http://www.wikidata.org/entity/Q44484456

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年学术文章

@wuu

2003年学术文章

@zh-cn

2003年学术文章

@zh-hans

2003年学术文章

@zh-my

2003年学术文章

@zh-sg

2003年學術文章

@yue

2003年學術文章

@zh

2003年學術文章

@zh-hant

name

NVP-LAQ824 is a potent novel h ...... vity against multiple myeloma.

@en

NVP-LAQ824 is a potent novel h ...... vity against multiple myeloma.

@nl

type

label

NVP-LAQ824 is a potent novel h ...... vity against multiple myeloma.

@en

NVP-LAQ824 is a potent novel h ...... vity against multiple myeloma.

@nl

prefLabel

NVP-LAQ824 is a potent novel h ...... vity against multiple myeloma.

@en

NVP-LAQ824 is a potent novel h ...... vity against multiple myeloma.

@nl

P1433

Q44484456-FB990AF2-B9BB-4A75-889C-D6BDED89B2A8

P1476

Q44484456-0143DA69-7B3D-410A-87F0-837AC232ED23

P2093

Q44484456-2573F1F5-B170-48AB-9DF3-DBEBD6804CE0

Q44484456-399DF900-D77A-400B-844D-C2C6FC8C8C3A

Q44484456-5F05F35C-6023-4895-B583-125A725FC351

Q44484456-6D291D35-3E6C-4E71-9FC1-5FE03BD457AD

Q44484456-8279F64F-160D-419D-BACB-92FB5890570B

Q44484456-89FDF879-A6D3-4FE1-B0F1-D1034EB8FB9A

Q44484456-8D22C951-1760-406E-A552-F4179E4D7B8C

Q44484456-9218EC41-D412-4CDE-9001-A573729581A5

Q44484456-9230A139-8A6C-4876-9985-BED0CDDC72C3

Q44484456-A02BABE2-F3D1-41ED-BA9F-7C6C068D284D

P304

Q44484456-3B857625-D8E9-4404-8F9E-B57022B094E2

P31

Q44484456-82768CB8-F5AE-4E31-A85C-5CED395410CA

P356

Q44484456-16F92EE4-EC4E-40A0-A4C8-5441873C02C8

P407

Q44484456-D65EFFB4-9142-41BA-B5CD-AD8031CA3076

P433

Q44484456-44A6FE85-0732-48BF-BF27-D0574BF5BE57

P478

Q44484456-9C90B7AE-6832-42E1-947E-A879733DA4F6

P50

Q44484456-3AAC59B4-CF7E-4940-ABE4-EFA26B830BED

Q44484456-68611190-6C44-445D-8523-B030C441939E

P577

Q44484456-FEDBE0FE-6A18-4D95-92A6-5B1E59357428

P5875

Q44484456-DC5CB64B-0D73-472B-A130-28D9E07377B9

P698

Q44484456-5A57906D-CDDF-40CB-AA9C-2FC84536D3B2

P356

BLOOD-2003-01-0233

P1433

P1476

NVP-LAQ824 is a potent novel h ...... vity against multiple myeloma.

@en

P2093

Dharminder Chauhan

http://www.w3.org/2001/XMLSchema#string

Ellen Weisberg

http://www.w3.org/2001/XMLSchema#string

James Griffin

http://www.w3.org/2001/XMLSchema#string

Laurence Catley

http://www.w3.org/2001/XMLSchema#string

Nicholas Mitsiades

http://www.w3.org/2001/XMLSchema#string

Nikhil C Munshi

http://www.w3.org/2001/XMLSchema#string

Peter Atadja

http://www.w3.org/2001/XMLSchema#string

Reshma Shringarpure

http://www.w3.org/2001/XMLSchema#string

Richard LeBlanc

http://www.w3.org/2001/XMLSchema#string

Robert Schlossman

http://www.w3.org/2001/XMLSchema#string

P304

2615-2622

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2003-01-0233

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

102

http://www.w3.org/2001/XMLSchema#string

P50

Kenneth C Anderson

Paul G Richardson

P577

2003-06-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

10699119

http://www.w3.org/2001/XMLSchema#string

P698

12816865

http://www.w3.org/2001/XMLSchema#string